Nelarabine‐combined chemotherapy improves outcome of T‐cell acute lymphoblastic leukemia but shows more severe neurotoxicity: JALSG T‐ ALL213 ‐O
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
We investigated the effectiveness and safety of nelarabine (NEL)-combined chemotherapy for newly diagnosed adult T-cell acute lymphoblastic leukemia (T-ALL) patients. We conducted a phase II trial, T-ALL213-O, where adult T-ALL patients aged 25 to 64 were treated by a regimen based on that used in our previous study, ALL202-O. The main modifications from ALL202-O to T-ALL213-O were as follows: (1) NEL-combined chemotherapy, instead of consolidation (C)1, was used for non-complete remission (CR) patients after induction therapy (IND)1 as IND2; (2) NEL treatments were inserted into C3 and C5 on day 29. Twenty-four patients were analyzed. Ten patients did not receive NEL treatment due to therapy termination prior to C3. Three-year event-free survival (EFS) was 70%, with 52% as the lower limit of its 90% confidence interval, which exceeded the threshold of 25%; thus, the study treatment was considered effective. The CR rates by IND1, IND2, and both were 75%, 100%, and 88%, respectively. The 5-year EFS and 5-year overall survival rates were 66% and 70%, respectively, with median follow-ups of 7.7 and 7.8 years. The addition of NEL improved the CR rate but not survival, compared with T-ALL patients in ALL202-O. Severe neuropathy after NEL administration was observed at a high frequency. Seven (50%) of 14 patients treated with NEL showed grade 3 peripheral neuropathy and/or gait disturbance. The neurotoxicity was considered stronger than that previously reported. Combination therapy of NEL at this dose and intensive multidrug chemotherapy is associated with a high risk of severe neurotoxicity (JALSG T-ALL213-O, UMIN000010642).
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Nelarabine‐combined chemotherapy improves outcome of T‐cell acute lymphoblastic leukemia but shows more severe neurotoxicity: <scp>JALSG</scp> T‐<scp>ALL213</scp>‐O
- Date Crossref
- 21/11/2024
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Nagoya University Division of Cellular and Genetic Sciences pays non établi dans la noticeUniversité ou école supérieure
-
International University of Health and Welfare Department of Hematology/Preventive Medicine pays non établi dans la noticeUniversité ou école supérieure
-
University of Tsukuba Department of Hematology pays non établi dans la noticeUniversité ou école supérieure
-
Sendai Medical Center Department of Hematology pays non établi dans la noticeÉtablissement de santé
-
Jikei University School of Medicine Division of Clinical Oncology/Hematology pays non établi dans la noticeUniversité ou école supérieure
-
Hyogo Prefectural Cancer Center pays non établi dans la noticeÉtablissement de santé
-
Yokohama Rosai Hospital Department of Hematology pays non établi dans la noticeÉtablissement de santé
-
Nagasaki University Department of Hematology and Molecular Medicine Unit pays non établi dans la noticeUniversité ou école supérieure
-
The Japanese Data Center for Hematopoietic Cell Transplantation pays non établi dans la noticeStructure de recherche
-
Chiba University Hospital Department of Hematology pays non établi dans la noticeÉtablissement de santé
-
Nihon University pays non établi dans la noticeUniversité ou école supérieure
-
Kindai University pays non établi dans la noticeUniversité ou école supérieure
Division of Cellular and Genetic Sciences — Nagoya University, Department of Hematology/Preventive Medicine — International University of Health and Welfare et Department of Hematology — University of Tsukuba, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.